ESMO 2014: Sessions of Interest for Reporters
A preliminary selection of regular abstracts and other sessions that are potentially interesting for reporters
Molecular profiling of cancer
Precision medicine: Panacea or false dawn?
Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC)
Neoadjuvant treatment with docetaxel plus lapatinib (L), trastuzumab (T), or both followed by an anthracycline based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study
MAGRIT, a double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of the recMAGE-A3 + AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (NSCLC)